Continuing Pharmacy Education / ACPE Topic Designation / Tumor Immunotherapy: Chimeric Antigen Receptor (CAR) T Cell Therapy
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Tumor Immunotherapy: Chimeric Antigen Receptor (CAR) T Cell Therapy

Learning Objectives

At the end of this knowledge-based continuing education activity, the learner will be able to:

  1. Describe the mechanisms underlying CAR-T cell therapy
  2. Describe the role of CAR-T cell therapy in B-cell malignancies
  3. Discuss the development of CAR T cell therapy for solid tumors.
  4. Identify toxicities associated with CAR-T cell therapy
  5. Describe the clinical management of CAR-T cell toxicities

Release Date:

Release Date: September 30, 2020

Expiration Date: September 30, 2023

Course Fee

FREE

Session Codes

Pharmacist: 20RC55-WTX94

Accreditation Hours

1.0 hour of CE

Accreditation Statements

The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-20-055-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Faculty

Trinh Pham, PharmD, BCOP
Clinical Specialist
YNHH, Smilow Cancer Hospital
Oncology Pharmacy Services
New Haven, CT

Grant Funding:

 

A grant was provided for partial funding of the above activities by Bristol Meyers Squibb.

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Trinh Pharm PharmD, BCOP, has no relationship with an ineligible company and therefore has nothing to disclose.

Disclosure of Discussions of Off-label and Investigational Drug Use

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Content-See Video Above

Pharmacist Post Test (for viewing only)

This test is for viewing purposes only. If you would like to submit the test, go to the blue button at the top of the page or  Test/Evaluation Site.

 

Pharmacist Post Test

 

Which of the following is an FDA approved indication for CAR T‐Cell therapy?
a. Basel cell carcinoma
b. Urothelial carcinoma
c. Multiple myeloma

Choose the CORRECT statement regarding therapy with CAR T-cells
a. CAR T-cells are derived from multiple matched donors
b. CAR T-cells targets CD4+ and CD20+ cells
c. Chemotherapy is necessary prior to CAR T-cell therapy

Which of the following is a limitation of CAR‐T cell therapy?
a. Loss of antigen from the tumor
b. T‐Cell proliferation and activation
c. B cell lymphoma and leukemia

Which of the following is a risk factor for the development of CRS or neurotoxicity with CAR T-cell therapy?
a. High tumor burden
b. Children as patients
d. Minimal CAR T-cell dose

Challenges of CAR T cell therapy in treating solid tumors include:
a. Toxicities such as hepatitis
b. Tumor immunosuppression
c. Treating only chronic toxicities

References

Full List of References

References at end of video